A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (NCT04626635)
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)
Who can join: Review the eligibility criteria below.
Location: Valkyrie Clinical Trials — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (54 Sites)
Showing the first 25 of 54 sites.
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles (UCLA) Medical Center — Los Angeles, California
- The Regents of the University of California, San Francisco — San Francisco, California
- University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic — Aurora, Colorado
- University of Florida Health — Gainesville, Florida
- Moffitt Cancer Center — Tampa, Florida
- University of Illinois Cancer Center — Chicago, Illinois
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- START Midwest - Cancer & Hematology Centers of Western Michigan, PC — Grand Rapids, Michigan
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Cincinnati Medical Center — Cincinnati, Ohio
- The Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute - 25th Ave — Nashville, Tennessee
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- South Texas Oncology And Hematology — San Antonio, Texas
- University of Washington/Fred Hutchinson Cancer Center — Seattle, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Centre Leon Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL) — Lyon, Auvergne-Rhone
- Hopital Lyon Sud — Pierre-Bénite, Auvergne-Rhône
- Centre Georges Francois Leclerc — Dijon, Bourgogne-Franche-Comté
- Institut Claudius Regaud, IUCT-Oncopole — Toulouse, Haute-Garonne
- Centre Hospitalier Universitaire (CHU) de Lille — Lille, Hauts-de-France
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.